Barclays analyst Carter Gould maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of $43.00. The company’s shares closed yesterday at $44.70.
Gould covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, AbbVie, and Biogen. According to TipRanks, Gould has an average return of 8.2% and a 55.41% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for Bristol-Myers Squibb with a $54.21 average price target, which is a 21.28% upside from current levels. In a report released yesterday, Bank of America Securities also maintained a Hold rating on the stock with a $60.00 price target.
BMY market cap is currently $99.29B and has a P/E ratio of 12.69.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bristol-Myers Squibb (BMY) Company Description:
Founded in 1933, New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in the development, licensing, manufacturing, distribution, and sale of biopharmaceutical products in several therapeutic areas. These include cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Read More on BMY:
